Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...

A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Tuesday reported encouraging results from its Phase 2 study of MariTide in people with obesity. Results from the 2 ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent ...